Despite Patent Expiries of Leading Therapies, New Product Launches Will Drive a $4.6 Billion Increase in the Coronary Heart Disease Market
Posted on: Tuesday, 24 March 2009, 07:00 CDT
Growth Will be Driven by Drugs from Eli Lilly/Daiichi Sankyo, AstraZeneca, and Schering-Plough, According to a New Report from Decision Resources
The new Pharmacor report entitled Coronary Heart Disease finds that the market to treat the disease will grow from
Despite the patent expiry of the two sales-leading coronary heart disease therapies by 2012 -- Sanofi-Aventis/Bristol-Myers Squibb's Plavix/Iscover and Pfizer's Lipitor -- the market entry of fixed-dose combinations with agents such as Abbott's Tricor/TriLipix, Solvay's Lipanthyl and Abbott's Niaspan will also offset the negative impact of generic erosion, according to the report.
"Cardiologists' approach to coronary heart disease therapy has experienced a remarkable international convergence as optimal drug treatment for post-myocardial infarction -- the condition that accounts for more than 70 percent of coronary heart disease market sales -- now consists of two antiplatelet agents, including aspirin, a statin, an ACE inhibitor and a beta blocker," said Decision Resources Therapeutic Area Director
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Decision Resources Decision Resources, Inc. Christopher Comfort Elizabeth Marshall 781-296-2597 781-296-2563 ccomfort@dresources.com emarshall@dresources.comSOURCE Decision Resources
Source: PR Newswire
Related Articles
- Rules-Based Medicine, Inc. Names Don Beamish to Lead Sales & Marketing for Diagnostics Expansion
- New Therapies, Including Novel Biologic Agents from Elan/Wyeth and Eli Lilly, Will Drive Robust 11 Percent Annual Growth In the Alzheimer's Disease Market
- Frost & Sullivan to Host Analyst Briefing on the European Orphan Diseases Market: Niche-Busters - An Attractive Future?
- Parkinson's Disease Market Upgrade Following Evidence of Disease Slowing With Azilect
- Groundbreaking Apo E Gene Diet Linked to Alzheimer's Disease and Heart Disease Prevention
- Research and Markets: The Parkinsons Disease Market Is Set To Continue To Grow Over The Next 7 Years, Reaching Over $2.37 Billion In 2013, A 39% Increase From 2006 Levels
- Lung Cancer is the Third Most Common Malignant Disease and the First Leading Cause of Cancer Death in the Western World
- Clinical Data Adds James P. Shaffer, Experienced Sales and Marketing Executive, to Lead Sales and Marketing Team for PGxHealth Division
- First Patient Enrolled in OXiGENE's Phase Ib Trial of Its Lead Vascular Disrupting Agent, CA4P, in Combination With an Antiangiogenic Agent, Bevacizumab (Avastin) for the Treatment of Advanced Cancer
 |
 |
User Comments (0)
RSS Feeds